



October 7, 2024

VIA EMAIL AND REGULAR MAIL

Suzie Welsh Devine, CEO  
Binto  
1516 N. 5th St., Suite 116  
Philadelphia, PA 19122  
suzie@mybinto.com

Re: Binto's Menopause Supplement Marketing Practices

Dear Ms. Devine:

On behalf of Truth in Advertising, Inc. ("TINA.org"), a nonprofit consumer advocacy organization dedicated to protecting consumers from deceptive advertising, we write to alert you to a deceptive marketing trend that is currently prevalent in the menopause supplement industry. Namely, many menopause supplements are marketed without the necessary scientific substantiation required by the FTC or the required FDA approval.

First, companies in this industry are marketing their supplements as treating menopause and its symptoms without competent and reliable scientific evidence to substantiate their claims, in violation of the Federal Trade Commission Act.<sup>1</sup> In general, "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing to meet the competent and reliable scientific standard."<sup>2</sup> Advertising a product's attributes – including a product's ability to treat menopause symptoms<sup>3</sup> – without substantiation to back up those claims constitutes deceptive marketing.<sup>4</sup>

Second, as made clear in several FDA warning letters, as well as agency drug approvals, in order to market products as able to treat menopause<sup>5</sup> and many of its symptoms (including, for example, moderate to severe hot flashes and night sweats,<sup>6</sup> moderate to severe vaginal pain and dryness,<sup>7</sup> depression and anxiety,<sup>8</sup> cognitive function,<sup>9</sup> insomnia,<sup>10</sup> and joint and muscle pain<sup>11</sup>), marketers must first obtain FDA approval, which supplement companies generally do not have. As such, marketers of menopause supplements should take care to ensure that their products are not being advertised as drugs without the requisite FDA approval.<sup>12</sup>

TINA.org urges Binto to review its marketing, which includes, among other things, claims that its Menopause Relief Kit can "Reduce and prevent hot flashes" and "Improve sleep"<sup>13</sup> and take the necessary steps to ensure compliance with FTC and FDA law.

If you have any questions, please do not hesitate to contact us.

Sincerely,



Laura Smith, Esq., Legal Director

Eliza Duggan, Esq.

Truth in Advertising, Inc.

---

<sup>1</sup> See FTC, Advertising Substantiation Principles,

<https://www.ftc.gov/sites/default/files/attachments/training-materials/substantiation.pdf>; FTC Health Products Compliance Guidance, [https://www.ftc.gov/system/files/ftc\\_gov/pdf/Health-Products-Compliance-Guidance.pdf](https://www.ftc.gov/system/files/ftc_gov/pdf/Health-Products-Compliance-Guidance.pdf).

<sup>2</sup> FTC Health Products Compliance Guidance, 12, [https://www.ftc.gov/system/files/ftc\\_gov/pdf/Health-Products-Compliance-Guidance.pdf](https://www.ftc.gov/system/files/ftc_gov/pdf/Health-Products-Compliance-Guidance.pdf). Further, advertisers relying on ingredient studies should consult with a qualified expert in the relevant field to determine whether a clinical study of the product itself is required, rather than reliance on isolated ingredient studies, to substantiate benefits. *Id.* at 13.

<sup>3</sup> Stipulated Order, *FTC v. Lunada Biomedical et al.*, C.D. Cal, May 16, 2020, Case 2:15-cv-03380 (preventing defendants from representing that their menopause supplement “relieves hot flashes, night sweats, irritability, mood swings, inability to concentrate, sleeplessness, lack of energy, decreased libido, stress, anxiety, weight gain, headache, or muscle or joint aches associated with menopause” without randomized, double-blind, placebo-controlled human clinical testing that substantiates that the representation is true, and requiring defendants to pay \$40 million).

<sup>4</sup> Specifically with respect to vasomotor symptoms – e.g., hot flashes and night sweats, the most common symptoms of menopause – it is worth noting that The North American Menopause Society, the nation’s preeminent resource on menopause to both healthcare providers and the public, has indicated that there is not sufficient evidence-based scientific research to substantiate claims that supplements can effectively relieve vasomotor symptoms of menopause. Chrisandra L. Shufelt et al, *The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society*, 30 *Menopause: J. North Am. Menopause Soc’y* 573-590, <https://www.menopause.org/docs/default-source/professional/2023-nonhormone-therapy-position-statement.pdf>.

<sup>5</sup> See, e.g., FDA warning letter to Bonagens, Nov. 17, 2020, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bonagens-609905-11172020> (“Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:… ‘alleviate the effects of menopausal syndrome … menopausal and sleeping disorders’”).

<sup>6</sup> See Veozah Highlights of Prescribing Information,

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/216578s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s0001bl.pdf) (“VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.”);

Brisdelle Highlights of Prescribing Information,

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/204516s0001bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204516s0001bl.pdf) (“BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.”).

<sup>7</sup> Ospheha Highlights of Prescribing Information,

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2019/203505s0151bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203505s0151bl.pdf) (“INDICATIONS AND USAGE... The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause[;] The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.”).

<sup>8</sup> See, e.g., FDA warning letter to Muscle Sports Products, LLC, Sept. 23, 2022, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/muscle-sports-products-llc-625731-09232022> (“Examples of some of the website claims that provide evidence that your products are intended for use as drugs

---

include: ... ‘Has been noted to have powerful reductions in anxiety’’); FDA warning letter to Enlifty, LLC, Feb. 18, 2021, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/enlifty-llc-612253-02182021> (“Examples of some of the website claims that provide evidence that your “Enlifty Mood Elevator” and “Enlifty Anxiety” are intended for use as drugs include: ... ‘The Only Doctor Designed Depression Pill, Enlifty Depression Supplement – Best Natural Antidepressant.’ ... ‘ENLIFTA: OUR #1 BEST-SELLING DEPRESSION SUPPLEMENT’... ‘A new natural supplement is providing relief to people across America suffering with severe anxiety and stress!’... ‘Unlike other supplements and prescription medications, Enlifty Anxiety helps to manage stress and associated anxiety without causing excess fatigue’... ‘for the treatment of insomnia and anxiety’’”).

<sup>9</sup> See, e.g., FDA warning letter to Beeyoutiful.com, LLC, July 12, 2021, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/beeyoutifulcom-llc-613682-07122021> (“Examples of some of the claims observed on your www.beeyoutiful.com website that provide evidence that your products are intended for use as drugs include: . . . On the product page, under the Product Description tab (in the ‘Who can benefit from taking Omega 3?’ section): ... ‘4. Cognitive function – including both dementia/Alzheimer’s and Depression/Mental disorders...’’); FDA warning letter to Let’s Talk Health, Inc., Aug. 6, 2019, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lets-talk-health-inc-576771-08062019> (“Examples of the claims that provide evidence that your products are intended for use as drugs include the following: . . . vii. ‘Carnitine . . . [has been used to show significant improvement in those with] mild cognitive impairment.’”).

<sup>10</sup> See, e.g., FDA warning letter to Enlifty, LLC, Feb. 18, 2021, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/enlifty-llc-612253-02182021> (“Examples of some of the website claims that provide evidence that your “Enlifty Mood Elevator” and “Enlifty Anxiety” are intended for use as drugs include: ‘... for the treatment of insomnia and anxiety’’”).

<sup>11</sup> See, e.g., FDA warning letter to The Truth Company, LLC, Nov. 14, 2022, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/truth-company-llc-611501-11142022> (“Examples of some of the website claims that provide evidence that your products are intended for use as drugs include: ... ‘zuRelief: Reduce Pain...’... ‘I am an MD and there is no product on the conventional over the counter market that approaches the combination of safety and effectiveness of zuRelief for my own joint and muscle aches.’”); FDA warning letter to ActiveHerb Technology, Inc., May 15, 2019, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/activeherb-technology-inc-574615-05152019> (“Examples of some of the labeling claims that provide evidence that your products are intended for use as drugs include: ... JointsJoy... ‘shown to inhibit inflammation reactions and to inhibit pain’... ‘relieves pain’... ‘relieve muscle aches’”); FDA warning letter to Emmbros Overseas Lifestyle PVT LTD., Feb. 5, 2019, <https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/emmbros-overseas-lifestyle-pvt-ltd-565631-02052019> (“Examples of some of the claims observed on your websites that provide evidence that your products are intended for use as drugs include the following: . . . ‘If you are suffering from joint pain & inflammation, the recommended dosage is 2 Arthcare Capsules...’’”).

<sup>12</sup> In addition to approving Veozah, Brisdelle, and Ospheña for the treatment of menopause symptoms, as well as several hormone therapies for menopause, the FDA has also approved one other drug for the treatment of conditions associated with menopause. Evista Highlights of Prescribing Information, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/020815s0341bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020815s0341bl.pdf) (Evista is approved for the treatment and prevention of osteoporosis and reduction of invasive breast cancer in postmenopausal women). See also Menopause: Medicines to Help You, FDA, <https://www.fda.gov/consumers/free-publications-women/menopause-medicines-help-you>.

<sup>13</sup> See, e.g., Relief Kit | Menopause Support, Binto, <https://mybinto.com/products/relief-kit-menopause-support>.